Serum pepsinogen 1 (SPG1) and anti-Helicobacter pylori serology have been used for gastric risk stratification in Asia.
Dr Song and colleagues from Maryland, USA assessed the utility of these markers in a Western population.
SPG1 measurements were available for 21 895 Finnish male smokers in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study.
The team used Cox proportional hazards models adjusted for potential confounders to estimate gastric cancer hazard ratios and 95% confidence intervals for low SPG1.
The researchers identified that 329 gastric cancers were diagnosed an average of 14 years after baseline.
Pre-diagnostic low SPG1 was significantly associated with increased gastric cancer risk.
The research team found that CagA seropositives had significantly higher odds ratios than CagA seronegatives.
Dr Song's team concludes, "Low SPG1 was associated with increased gastric cancer risk in our large Finnish cohort."
"A single measurement of SPG1 along with H. pylori whole cell and CagA serology provides potentially useful prediction of gastric cancer risk."